A Phase 2 Study of Budoprutug in Subjects With Primary Membranous Nephropathy
Climb Bio, Inc. · NCT07096843
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 18–75 · All sexes
- Healthy volunteers
- Not accepted (a condition is required)
- Study type
- Interventional · Phase 2
- Target enrollment
- 45
- US sites recruiting
- 6
- Study start
- August 25, 2025
- Record last updated
- October 8, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
To evaluate the safety and tolerability of three dose regimens of budoprutug in subjects with PMN
Being studied: budoprutug
Conditions: Primary Membranous Nephropathy
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- Confirmed diagnosis of PMN with positive anti-PLA2R antibodies
- CD19+ B cell count ≥40 cells/μL
- UPCR ≥2.0 g/g
- eGFR ≥35 mL/min/1.73 m²
- Stable RAAS inhibitor therapy
- Blood pressure \<150/90 mmHg at baseline
- Adequate hematologic, hepatic, and renal function
- Willing to use effective contraception (both sexes)
- Other inclusion criteria may apply
Exclusion Criteria
- Secondary Membranous Nephropathy
- Rapidly progressive glomerulonephritis or other glomerulopathies
- Prior B cell-depleting therapy within 24 weeks
- Recent use of immunosuppressants
- Active or high-risk infections
- History of malignancy
- Pregnancy or breastfeeding
- Recent major surgery or hospitalization
- Other exclusion criteria may apply
Recruiting US locations
Climb Bio Investigative Site #110
Denver, CO 80220
Climb Bio Investigative Site #105
Orlando, FL 32086
Climb Bio Investigative Site #108
Atlanta, GA 30342
Climb Bio Investigative Site #106
Indianapolis, IN 46268
Climb Bio Investigative Site #101
Clifton Park, NY 12065
Climb Bio Investigative Site #104
Sherman, TX 75092
Study contacts (from the official record)
- Climb Bio Study Director · +1 866 857 2596 · clinicaltrials@climbbio.com